orthopedic-devices.jpg

Global Orthopedic Device Industry to Reach $62.6 Billion by 2022 – Research and Markets

Posted On June 9, 2017 By OrthoSpineNews In Financial /  

June 09, 2017

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Growth Opportunities in the Global Orthopedic Device Industry” report to their offering.

The global orthopedic device industry looks attractive with opportunities in public and private hospitals. The global orthopedic device industry is expected to reach an estimated $62.6 billion by 2022 and is forecast to grow at a CAGR of 5.5% from 2017 to 2022. The major drivers for the growth of this market are the increasing aging population, increasing adoption of advancements in medical technologies, and growing healthcare expenditure and awareness.

Emerging trends, which have a direct impact on the dynamics of the orthopedic device industry, include the increasing demand for smart implants, the widening use of nanotechnologies, and the adoption of robotic surgery to increase mechanical performance and accuracy.

Orthopedic device companies profiled in this industry include DePuy Synthes, Zimmer Biomet Holding Inc., Stryker Corporation, Smith and Nephew PLC, and Medtronic are among the major manufacturers of orthopedic devices. Some of these companies are also pursuing mergers and acquisitions as strategic initiatives for driving growth.

Within the global orthopedic device industry, orthopedic reconstruction is expected to remain the largest segment by device type. With the rise of orthopedic disorders and increasing aging population are the major driving forces that will spur growth for this segment over the forecast period.

Companies Mentioned

  • Arthrex Inc.
  • DJO Global Inc.
  • Globus Medical Inc.
  • Johnson and Johnson (DePuy Synthes)
  • Medtronic
  • Smith & Nephew PLC
  • Stryker Corporation
  • Zimmer Biomet Holding Inc.

Key Topics Covered:

1. Executive Summary

2. Market Background and Classifications

3. Market Trends and Forecast Analysis from 2011 to 2022

4. Market Trends and Forecast Analysis by Region

5. Competitor Analysis

6. Cost Structure Analysis

7. Growth Opportunities and Strategic Analysis

8. Company Profiles of Leading Players

For more information about this report visit http://www.researchandmarkets.com/research/6lfb7t/growth

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Orthopedic Devices

Read More
1660e14.png

Amedica Releases 2016 Preliminary Earnings Report and Business Update

Posted On June 8, 2017 By OrthoSpineNews In Financial /  

SALT LAKE CITY, UT–(Marketwired – Jun 8, 2017) – Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, today announced its preliminary earnings report for the fourth quarter and fiscal year ended December 31, 2016 and provided a business update related to its business strategy and certain recent developments.

2016 PRELIMINARY EARNINGS REPORT

Amedica reported preliminary revenue of $3.6 million for the fourth quarter of 2016 and $15.2 million for the full year. Preliminary GAAP net loss for the fourth quarter of 2016 was $0.16 per share, compared to net loss of $0.57 per share in the fourth quarter of 2015. For the full year, the company reported preliminary GAAP net loss of $1.19 per share, compared to a net loss of $5.50 per share in 2015. The company’s cash and cash equivalents were $6.9 million at December 31, 2016, a decrease of $4.5 million from December 31, 2015.

In collaboration with its auditors, Amedica continues to consider any potential impairment in relation to certain of its long-lived assets. Once this exercise is completed, the Company will promptly complete its Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and file it with the SEC. Upon filing of the annual report the Company also expects to promptly file its quarterly report on Form 10-Q for the first quarter ended March 31, 2017.

BUSINESS UPDATE AND RELATED DEVELOPMENTS

Financial Update

The company has reduced its total debt to approximately $4 million, down from $24.3 million in July 2015 and from $36 million in late 2014. All debt will retire by January 2018, or sooner. Absent new financing, Amedica expects to be compliant with its debt covenants under the Hercules loan through July 2017. The company’s monthly cash burn rate has decreased from $2.8 million in 2014 to $1.3 million per month. Exclusive of principal and interest payments on the debt, the monthly operating cash burn rate is approximately $500,000. Staff count is now 35, compared to 56 last year, and greater than 100 in late 2014, as the company continues to focus on cost controls in-line with its October 2016 reorganization.

Commercialization Report

The Alpha launch of Amedica’s Taurus™ Pedicle Screw System, a spine fixation product line that received FDA clearance in November 2016, has completed over 60 surgeries, generating a total of $450,000 in new revenue with 10 new surgeons trialing the system for the first time. The company expects the Beta launch in mid-summer as additional instrument sets become available for new surgeon users.

Amedica continues to promote its Valeo ® line of silicon nitride spine implants with the addition of new surgeon users and distributors. With solid material science data supporting its silicon nitride, the company is now focused on clinical studies. The company has been successful in entering purchasing agreements for its products with multiple national and regional hospital groups. These purchasing agreements should lead to increased usage of the company’s products at those hospitals, resulting in increased revenue.

Other commercialization highlights include:

  • 12% increase in surgeons users since the end of 2016.
  • 10% increase in sales agents representing our products versus end of 2016, with a focus on improved management leading to increased productivity.
  • Multi-center clinical study initiated with long-term surgeon users of silicon nitride to examine results in a retrospective cohort of more than 1,000 patients.
  • Two new spine industry executives hired for Area Vice President and Vice President of Market Development positions; both with 20+ years of experience in the U.S. spine market.

Research and Development

Recent Research and Development Highlights:

  • Since the beginning of 2017, Amedica’s R&D group has published 10 peer-reviewed journal articles and 7 scientific proceedings on various aspects of silicon nitride. 7 additional manuscripts are in preparation or are at various stages of submission and peer review.
  • 4 additional patents awarded related to silicon nitride and other ceramic materials processes since 2015.
  • Already this year there have been 13 presentations made at scientific conferences including the American Academy of Orthopaedic Surgeons (AAOS), the Orthopedic Research Society (ORS), the Society for Biomaterials (SFB), and the Association of Bone and Joint Surgeons (ABJS), among others.
  • A recently-completed University of Rochester study re-confirmed that silicon nitride is resistant to bacteria, and has osteogenic properties.
  • As previously announced, Amedica completed five million cycle (Mc) wear testing of silicon nitride femoral heads in comparison to the industry-standard zirconia-toughened alumina (ZTA). Silicon nitride produced less wear, and less oxidative damage to the polyethylene than ZTA. Testing is continuing through 12 million cycles. Additional testing of the corrosion resistance of silicon nitride femoral heads is in progress toward a regulatory filing.
  • The company is testing the friction and wear behavior of polished silicon nitride against native cartilage. If successful, this project will open hemi-arthroplasty applications in several anatomic joint reconstructions, where native cartilage is partially preserved.
  • In large-animal testing, 12-week data have shown greater bone formation within porous silicon nitride than porous titanium. A separate large-animal spine fusion model with Amedica’s silicon nitride spacers showed greater bone formation than PEEK at the six-month study end-point.
  • The company entered a multi-year agreement with Texas A&M University’s School of Dentistry to evaluate silicon nitride in maxillofacial surgery, where osteogenic and antimicrobial properties are highly desirable. This partnership is expected to yield funding from the U.S. National Institute of Health (NIH) and the Small Business Innovative Research (SBIR) programs to continue support for Amedica’s R&D efforts.

Clinical and Regulatory

Results from Amedica’s CASCADE clinical trial showing effective spine fusion with porous silicon nitride without added bone graft are now published in the European Spine Journal. A similar trial (SNAP) compared silicon nitride to PEEK in lumbar fusion; preliminary data from the SNAP trial are consistent with previous observations that silicon nitride shows enhanced and earlier spine fusion than PEEK.

In December 2016, Amedica re-filed an application with the FDA with a modified porous (cancellous structured ceramic) cervical implant. After a 510(k) pre-submission meeting, the company is using FDA feedback to prepare a 510k submission to be filed in October 2017.

In 2017, Amedica’s Quality and Regulatory systems were audited exhaustively by the U.S. FDA and ANVISA — Brazil’s equivalent to the FDA — and the company is fully compliant with these regulatory bodies.

Strategic Direction

“Going forward, we are focused on growing spine sales, first and foremost, while pursuing a robust R&D program with academic and industry leaders, to assure leadership in medical ceramic technology,” said Dr. Bal, Chairman and CEO of Amedica. In addition to adding new U.S. surgeons, Amedica is aggressively targeting revenue opportunities in Brazil, Europe, and Australia, all markets where its silicon nitride implants are approved for sale. With recent submission of favorable clinical data to the Japan PMDA, the company expects approval in that market as well.

In addition to the ceramic femoral head development for the hip replacement market, Amedica has fabricated and tested a silicon nitride dental implant with FDA pre-submission, and expects FDA feedback in June 2017. A metal-ceramic brazing project with a global ceramics manufacturer is underway, targeting the total knee market, and composite devices in the spine market.

About Amedica Corporation

Amedica is focused on the development and application of spinal interbody implants made with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s products are manufactured in its ISO 13485 certified manufacturing facility, and it has a partnership with Kyocera, one of the world’s largest ceramic manufacturers. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM and private label partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements, which include statements regarding anticipated future revenues, FDA clearance of our products, addition of new surgeon users, and, results of clinical studies are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

CONTACT INFORMATION

Read More
news_FDA-Approval.jpg

Trice Medical Closes $19.3 Million Series C Financing To Address Increased Demand For Mi-Eye

Posted On June 8, 2017 By OrthoSpineNews In Financial /  

KING OF PRUSSIA, Pa., June 6, 2017 /PRNewswire/ — Trice Medical announced today that it closed a $19.3 million Series C financing and will use the proceeds to accelerate and expand the company’s U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. Smith & Nephew (LSE:SN, NYSE: SNN), a global medical technology business dedicated to helping healthcare professionals improve people’s lives, has taken a minority stake joining a consortium of current investors including Safeguard Scientifics (NYSE: SFE), HealthQuest Capital, BioStar Ventures and others in this latest funding round. To-date, Trice Medical has raised $40.9 million.

“This is a significant milestone for Trice Medical as we looking to expand our sales, marketing and commercialization efforts and bolster our workforce,” said Jeffrey O’Donnell, Sr., President and CEO at Trice Medical. “We’re proud to add Smith & Nephew to our list of investors and look forward to being able to leverage their global experience as we roll out additional mi-eye products in the future.”

The early success of Trice Medical’s mi-eye2™, which received FDA 510(K) clearance during the fourth quarter of 2016, has captured the attention of medical professionals who are embracing the technology as a replacement to the MRI. After the first few months of commercial launch, the mi-eye is currently being used by nearly 100 physician practices across 25 states. The disposable needle embedded with a wide-angle camera lens enables physicians to diagnose joint injuries from the office. The scope’s improved vision quality and non-invasive technique provides patients with a more complete diagnosis. As the competitive landscape continues to evolve, Trice Medical will allocate resources to research and development of the technology’s third generation.

Dr. Sean McMillan, Chief of Orthopedics at Our Lady of Lourdes, is a physician who has successfully integrated the mi-eye into his practice. “I am extremely excited to have the ability to offer safe, cutting edge technology to my patients,” said Dr. McMillan. “By using the mi-eye, my patients are able to obtain the answer to their cause of pain immediately and start their road to recovery 2 to 3 weeks quicker than if they had an MRI. The most exciting part about using the mi-eye is the increasing number of patients who are calling up and specifically asking for the procedure. Our patients are seeking out innovative technology that is both fast, convenient, and cost effective.”

O’Donnell continued, “This financial support from our existing and new investors gives us the runway we need to fulfill our mission – to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. We can now attract the talent we need to scale to make mi-eye the standard of care in diagnostic imaging.”

About Trice Medical
Trice Medical was founded to fundamentally improve orthopedic diagnostics for the patient, physician, and payor by providing instant answers. Trice Medical has pioneered fully integrated camera-enabled technology, the mi-eye 2, which provides a clinical solution optimized for the physician’s office. Trice Medical’s mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system. Trice Medical’s major investors include BioStar Ventures, HealthQuest Capital, Smith & Nephew and Safeguard Scientifics (NYSE: SFE). For more information, visit www.tricemedical.com; follow us on Twitter, LinkedIn and Facebook; or call 844.643.9300.

SOURCE Trice Medical

Related Links

http://www.tricemedical.com

Read More
AAEAAQAAAAAAAAfMAAAAJGE5NmNhN2ZjLWQyZjYtNGNkYy05OTUwLTM5MTliMGMxOWRjMQ.jpg

Medtronic, GlaxoSmithKline team up in $40M equity deal for back-pain startup

Posted On June 5, 2017 By OrthoSpineNews In Financial, Neuro /  

By kgrayson@bizjournals.com – May 30, 2017

Medtronic has joined in a $40 million round of equity financing for Saluda Medical, a med-tech company with operations in the Twin Cities.

Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses. The Australia-based company expanded into the United States two years ago, starting a seven-employee clinical research team in Bloomington, Minn.

The company plans to expand its Twin Cities operation following the round of funding, Saluda Medical Senior Vice President Dan Brounstein said in an email. “It is the place to start a medical device company and we are dedicated to continued growth.”

Action Potential Venture Capital, a venture arm of GlaxoSmithKline, led the round of funding. Medtronic was a return investor.

READ THE REST HERE

Read More
155748308.jpg

First Choice Announces Share Repurchase Plan

Posted On June 5, 2017 By OrthoSpineNews In Financial, Top Stories /  

MELBOURNE, FL–(Marketwired – Jun 2, 2017) – First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) (“FCHS,” “First Choice” or the “Company”), one of the nation’s only non-physician-owned, publicly traded healthcare services companies focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedics and spine care, today announced that its Board of Directors unanimously approved a program to repurchase up to one million shares of the company’s common stock.

The authorized repurchases will be made from time to time in either the open market, block transactions, or through privately negotiated transactions. The timing, volume and nature of share repurchases will be at the sole discretion of management, dependent on market conditions, applicable securities laws, and other factors, and may be suspended or discontinued at any time.

“The stock repurchase plan demonstrates our confidence in the strength of our business and commitment to delivering shareholder value,” said Chris Romandetti, President and CEO of First Choice. “We believe our valuation is attractive relative to industry peers and given the company has sufficient cash on hand to support our expansion plans, adding the flexibility to repurchase shares was prudent.”

No assurance can be given that any particular amount of common stock will be repurchased. This repurchase program has no expiration date and is subject to the company’s blackout periods. The program may be modified or terminated by the Board of Directors at any time. The Company will report the repurchases in its periodic reports filed with the U.S. Securities and Exchange Commission.

As of March 31, 2017, First Choice reported approximately $3.9 million in cash with an additional $1.4 million available on a credit facility. First Choice intends to use available cash and future cash flows from operations to fund the repurchase program.

About First Choice Healthcare Solutions, Inc.
Headquartered in Melbourne, Florida, First Choice Healthcare Solutions (FCHS) is implementing a defined growth strategy aimed at expanding its network of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services in key expansion markets throughout the Southeastern U.S. Serving Florida’s Space Coast, the Company’s flagship integrated platform currently administers over 100,000 patient visits each year and is comprised of First Choice Medical Group, The B.A.C.K. Center and Crane Creek Surgery Center. For more information, please visit www.myfchs.com, www.myfcmg.com, www.thebackcenter.net and www.cranecreeksurgerycenter.com.

Safe Harbor Statement
Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of First Choice Healthcare Solutions, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward-looking statements can be found in the Company’s periodic reports on Form 10-K and Form 10-Q, and in its Current Reports on Form 8-K, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.

CONTACT INFORMATION

Read More
arthrosight_home.png

Arthromeda Inc. Completes Successful Preclinical Studies and Closes Funding for Its ArthroSight Patient-Specific Navigation Platform

Posted On June 2, 2017 By OrthoSpineNews In Financial, Recon, Top Stories /  

LOWELL, Mass., June 1, 2017 /PRNewswire/ — Arthromeda, Inc., a developer of intelligent orthopedic navigation systems, closed its Series D financing to take the ArthroSight-PS Hip Alignment System (ArthroSight-PS) through commercial regulatory approvals and clinical validation.  This was achieved following a series of successful cadaver labs conducted by surgeon Daniel Ward, MD (New England Baptist Hospital, Boston, MA) at the Cincinnati Children’s Hospital and Medical Center translational research lab (Cincinnati, OH).  The cadaveric studies confirmed that the ArthroSight- PS is an intuitive All-in-One system for accurate and precise implant positioning, providing real-time position angles (inclination and anteversion), leg length and femoral offset difference measurements.  Videos from the labs can be found in Arthromeda’s newly released clinician and patient focused website www.arthromeda.com.

Accurate hip implant positioning is an extremely important factor for patients, physicians, regulators and device companies. In recent years, the number of hip surgeries has skyrocketed with increasing numbers of younger adults getting the procedure according to popular press reports.  Over the 10 years of the study, the number of procedures more than doubled, from 138,700 in 2000 to 310,800 in 2010. The number grew by 92 percent, to 80,000, among those aged 75 and older. It jumped by 205 percent in those aged 45 to 54, to 51,900. Due to the aging baby boomer population, the magnitude of the problem is projected to increase dramatically – doubling by 2030.

“Patient-specific solutions in surgery that are individualized to patients at an affordable cost are important. I am delighted to support Arthromeda in its game-changing mission to help patients undergoing hip arthroplasty experience superior outcomes,” commented Edgar D. Jannotta, Jr., Arthromeda Director and lead investor.

Elsa Chi Abruzzo, RAC, FRAPS, chief operating officer of Arthromeda, commented, “I am grateful to our founder and executive chairman, Mr. PJ Anand, for his clear strategic vision and leadership.  I also appreciate the technical insight of our cofounder and Chief Technical Officer, Mehran Aghazadeh, MD.  We are excited to execute on the next phase of development of this elegant solution for real-time, accurate, acetabular cup positioning and leg length and femoral offset adjustments, without the expensive capital investments or increased procedure time associated with robotic and imaged-based systems.”

Foley Hoag LLP, led by Life Sciences Practice chair Jeffrey Quillen and Patrick Connolly, represented Arthromeda in the financing.  Mr. Quillen & Connolly have represented Arthromeda since its founding in 2011.

About Arthromeda, Inc.

Founded in 2011, Arthromeda, Inc. is a private medical device company focused on developing intuitive, real-time, sensor based, intelligent technologies to improve surgical outcomes for patients undergoing joint replacement procedures.  As part of its extensive patent protected intellectual property portfolio, Arthromeda has created two distinct, yet complimentary, technology platforms to reduce operating room time, improve patient outcomes, and reduce the cost burden associated with early implant failure.   More information can be found at www.arthromeda.com

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org

 

SOURCE Arthromeda, Inc.

Related Links

http://www.arthromeda.com/

Read More
rti-surgical-corporate-photos-38.jpg

RTI Surgical® Partners in New Manufacturing USA Institute

Posted On June 2, 2017 By OrthoSpineNews In Biologics, Financial, Top Stories /  

June 02, 2017

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical (RTI) (Nasdaq: RTIX), a global surgical implant company, is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the twelfth Manufacturing USA institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.

Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute on behalf of the Department of Defense.

Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading advanced manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue biofabrication technology in order to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.

“We need to develop twenty-first century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a fifteenth century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.

ARMI’s efforts are supported by forty-seven industrial partners, twenty-six academic and academically affiliated partners, and fourteen government and nonprofit partners. The ARMI partnership continues to grow.

“RTI Surgical is pleased to participate in the ARMI consortium,” said Todd Goede, Global Vice President of Research and Development. “We look forward to providing the regenerative manufacturing resources and knowledge that we use every day to help patients – undoubtedly, the lives of many will benefit from the innovations this initiative will create.”

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

About ARMI

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is the 12th Manufacturing USA Institute. It brings together a consortium of nearly 100 partners from across industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI will work to organize the current fragmented domestic capabilities in tissue biofabrication technology to better position the U.S. relative to global competition. For more information on ARMI, please visit www.ARMIUSA.org.

Contacts

RTI Surgical
Roxane Wergin, Phone: 386-418-8888
Director, Corporate Communications
rwergin@rtix.com

Read More
1-SL-1050x525.jpg

Additive Manufacturing for Orthopedic Implants to Generate More Than $1B in Revenue Opportunities by 2026

Posted On June 1, 2017 By OrthoSpineNews In Financial /  

CROZET, VA, May 31, 2017 /24-7PressRelease/ —

SmarTech Publishing, the leading provider of in-depth industry analysis services to the additive manufacturing industry, has published its first ever true industry opportunity deep dive market research report on the burgeoning ‘additive orthopedics’ industry, revealing an area of well-defined opportunity for additive manufacturing that is being faced with sizeable change over the next several years.

Additive manufacturing technologies have been employed by orthopedic device manufacturers for the production of approved medical implants for almost a decade, however the use of such technology is at a critical tipping point today. SmarTech’s proprietary market models have been adapted to this growing serial manufacturing opportunity as part of its ongoing analysis plan in biomedical 3D printing/additive manufacturing, and reveal that the additive orthopedic market generated nearly $500M in total opportunities in 2016.

Details of the report titled, “Additive Orthopedics: Markets for 3D-Printed Medical Implants – 2017” are available at
https://www.smartechpublishing.com/reports/additive-orthopedics-marke … lants-2017

About the Report:

Use of additive manufacturing (AM) technologies for the production of approved orthopedic devices has been a driving force in the growth of metal AM technology to address true serial manufacturing applications. Today, the industry is rapidly expanding these efforts to include not only titanium implants in new orthopedic care segments, but also the use of polymer and bioactive materials and 3D printing technologies to revolutionize the future of orthopedic care using implantable devices.

READ THE REST HERE

 

Read More
IT19_Zbh_103116_company.jpg

Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2017

Posted On May 30, 2017 By OrthoSpineNews In Financial /  

WARSAW, Ind., May 30, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2017.

The cash dividend of $0.24 per share will be paid on or about July 28, 2017 to stockholders of record as of the close of business on June 23, 2017.  Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

 

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

www.zimmerbiomet.com

Read More
pexels-photo-236054-1.jpeg

Neuromonitoring Company Founded by Former NFL Quarterback Set to Go Public

Posted On May 30, 2017 By OrthoSpineNews In Financial, Neuro, Spine /  
Source: The Life Sciences Report – May 29, 2017

Assure Neuromonitoring, a wholly owned subsidiary of Assure Holdings Inc. (IOM:TSX.V), provides intraoperative neuromonitoring (IONM) services. The standard of care in the United States is to provide IONM services to monitor the nervous systems of patients undergoing invasive surgeries such as spine, ear, nose and throat, and others, to monitor the activity and warn the surgeon if he/she is getting close to a nerve, thereby preventing nerve damage.

Most IONM services are staffed by onsite technologists and offsite neurologists who are provided by third-party services, which does not provide consistency or accountability. According to the company, the Assure platform “employs its own staff of highly trained technologists and uses its own state of the art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided.” Assure’s technologists and neurologists are dedicated to specific surgeons and work as a team, thereby developing rapport and trust.

The company notes that “Assure has developed a comprehensive platform that engages all stakeholders including the surgeon, the technologist, the neurologist, and the patient.”

The company began operations in Colorado in 2015 and has primarily serviced spine surgeries. The company plans to expand into additional states and into additional types of surgeries.

 

READ THE REST HERE

 

Read More